260 related articles for article (PubMed ID: 35163076)
1. Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis.
Poznyak AV; Sukhorukov VN; Zhuravlev A; Orekhov NA; Kalmykov V; Orekhov AN
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163076
[TBL] [Abstract][Full Text] [Related]
2. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.
Li J; Zhu J; Cao B; Mao X
Curr Pharm Des; 2014; 20(1):125-35. PubMed ID: 24001224
[TBL] [Abstract][Full Text] [Related]
3. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression.
Huber TB; Walz G; Kuehn EW
Kidney Int; 2011 Mar; 79(5):502-11. PubMed ID: 21085109
[TBL] [Abstract][Full Text] [Related]
4. Role of Mammalian Target of Rapamycin in Atherosclerosis.
Cai Z; He Y; Chen Y
Curr Mol Med; 2018; 18(4):216-232. PubMed ID: 30259816
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin passes the torch: a new generation of mTOR inhibitors.
Benjamin D; Colombi M; Moroni C; Hall MN
Nat Rev Drug Discov; 2011 Oct; 10(11):868-80. PubMed ID: 22037041
[TBL] [Abstract][Full Text] [Related]
6. Molecular actions of sirolimus: sirolimus and mTor.
Kirken RA; Wang YL
Transplant Proc; 2003 May; 35(3 Suppl):227S-230S. PubMed ID: 12742500
[TBL] [Abstract][Full Text] [Related]
7. The Akt-mTOR pathway in Down's syndrome: the potential use of rapamycin/rapalogs for treating cognitive deficits.
Troca-Marín JA; Casañas JJ; Benito I; Montesinos ML
CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):34-40. PubMed ID: 24152334
[TBL] [Abstract][Full Text] [Related]
8. mTOR in the Mechanisms of Atherosclerosis and Cardiovascular Disease.
Liu Z; Fan Y; Zhang Z; Fang Y; Cheng X; Yang Q; Liu J; Xie J
Discov Med; 2021; 31(164):129-140. PubMed ID: 35188887
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
10. A nano-bioconjugate modified with anti-SIRPα antibodies and antisense oligonucleotides of mTOR for anti-atherosclerosis therapy.
Liu Y; Huang Q; He M; Chen T; Chu X
Acta Biomater; 2024 Mar; 176():356-366. PubMed ID: 38160854
[TBL] [Abstract][Full Text] [Related]
11. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
12. Targeting mTOR signaling pathway in ovarian cancer.
Mabuchi S; Hisamatsu T; Kimura T
Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond.
Lamming DW
Cold Spring Harb Perspect Med; 2016 May; 6(5):. PubMed ID: 27048303
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin Inhibits Oxidized Low Density Lipoprotein Uptake in Human Umbilical Vein Endothelial Cells via mTOR/NF-κB/LOX-1 Pathway.
Zhou YD; Cao XQ; Liu ZH; Cao YJ; Liu CF; Zhang YL; Xie Y
PLoS One; 2016; 11(1):e0146777. PubMed ID: 26752047
[TBL] [Abstract][Full Text] [Related]
15. Expression of miRNA-155 in carotid atherosclerotic plaques of apolipoprotein E knockout (ApoE
Ma J; Yang S; Ma A; Pan X; Wang H; Li N; Liu S; Wu M
Int Immunopharmacol; 2017 May; 46():70-74. PubMed ID: 28273556
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.
Rico C; Laguë MN; Lefèvre P; Tsoi M; Dodelet-Devillers A; Kumar V; Lapointe E; Paquet M; Nadeau MÈ; Boerboom D
Carcinogenesis; 2012 Nov; 33(11):2283-92. PubMed ID: 22871496
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
18. Targeting mTOR Signaling Can Prevent the Progression of FSGS.
Zschiedrich S; Bork T; Liang W; Wanner N; Eulenbruch K; Munder S; Hartleben B; Kretz O; Gerber S; Simons M; Viau A; Burtin M; Wei C; Reiser J; Herbach N; Rastaldi MP; Cohen CD; Tharaux PL; Terzi F; Walz G; Gödel M; Huber TB
J Am Soc Nephrol; 2017 Jul; 28(7):2144-2157. PubMed ID: 28270414
[TBL] [Abstract][Full Text] [Related]
19. Target of rapamycin (TOR)-based therapy for cardiomyopathy: evidence from zebrafish and human studies.
Kushwaha S; Xu X
Trends Cardiovasc Med; 2012 Feb; 22(2):39-43. PubMed ID: 22841839
[TBL] [Abstract][Full Text] [Related]
20. mTOR mediates the cross-talk of macrophage polarization and autophagy in atherosclerosis.
Tian F; Yu BL; Hu JR
Int J Cardiol; 2014 Nov; 177(1):144-5. PubMed ID: 25499362
[No Abstract] [Full Text] [Related]
[Next] [New Search]
